FY2026 EPS Estimates for Novartis Raised by Erste Group Bank

Novartis AG (NYSE:NVS) – Stock analysts at Erste Group Bank upped their FY2026 earnings per share estimates for shares of Novartis in a note issued to investors on Friday, September 18th. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $9.14 for the year, up from their prior estimate of $8.99. The consensus estimate for Novartis’ current full-year earnings is $8.87 per share.

Novartis (NYSE:NVS) last issued its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $14.95 billion during the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

NVS has been the topic of a number of other reports. Royal Bank Of Canada assumed coverage on Novartis in a research note on Tuesday, September 8th. They set a “sector perform” rating on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft lowered Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Finally, HSBC upgraded Novartis from a “reduce” rating to a “hold” rating and boosted their price objective for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Six analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Novartis currently has a consensus rating of “Hold” and a consensus target price of $153.00.

Novartis Price Performance

NVS stock opened at $142.60 on Tuesday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. The firm has a market cap of $272.10 billion, a P/E ratio of 21.51, a P/E/G ratio of 2.73 and a beta of 0.45. The firm’s fifty day moving average is $152.02 and its 200 day moving average is $151.49. Novartis has a 52 week low of $121.57 and a 52 week high of $170.46.

Institutional Trading of Novartis

Institutional investors have recently modified their holdings of the company. J.W. Cole Advisors Inc. grew its holdings in Novartis by 0.6% during the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock valued at $1,348,000 after buying an additional 64 shares in the last quarter. Roundview Capital LLC lifted its holdings in shares of Novartis by 2.5% in the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock worth $374,000 after buying an additional 66 shares in the last quarter. CPC Advisors LLC lifted its holdings in shares of Novartis by 4.6% in the second quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock worth $238,000 after buying an additional 66 shares in the last quarter. IMA Advisory Services Inc. boosted its position in shares of Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after acquiring an additional 70 shares during the last quarter. Finally, Moody National Bank Trust Division grew its stake in Novartis by 4.2% during the second quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock valued at $282,000 after acquiring an additional 72 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Novartis Company Profile

Novartis AG (NYSE: NVS) is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company’s portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.